JP2018515474A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515474A5 JP2018515474A5 JP2017556652A JP2017556652A JP2018515474A5 JP 2018515474 A5 JP2018515474 A5 JP 2018515474A5 JP 2017556652 A JP2017556652 A JP 2017556652A JP 2017556652 A JP2017556652 A JP 2017556652A JP 2018515474 A5 JP2018515474 A5 JP 2018515474A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- weeks
- administered
- tissue sample
- binding portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 7
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 7
- 201000001441 melanoma Diseases 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 238000005259 measurement Methods 0.000 claims 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 238000009097 single-agent therapy Methods 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 102000048362 human PDCD1 Human genes 0.000 claims 1
- 210000004969 inflammatory cell Anatomy 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021037372A JP2021105001A (ja) | 2015-04-28 | 2021-03-09 | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| JP2024018859A JP2024063028A (ja) | 2015-04-28 | 2024-02-09 | 抗ｐｄ－１抗体を使用するｐｄ－ｌ１陽性黒色腫の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562153954P | 2015-04-28 | 2015-04-28 | |
| US62/153,954 | 2015-04-28 | ||
| PCT/US2016/029878 WO2016176504A1 (en) | 2015-04-28 | 2016-04-28 | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021037372A Division JP2021105001A (ja) | 2015-04-28 | 2021-03-09 | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018515474A JP2018515474A (ja) | 2018-06-14 |
| JP2018515474A5 true JP2018515474A5 (https=) | 2019-06-13 |
Family
ID=56069213
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556652A Pending JP2018515474A (ja) | 2015-04-28 | 2016-04-28 | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| JP2021037372A Pending JP2021105001A (ja) | 2015-04-28 | 2021-03-09 | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| JP2024018859A Pending JP2024063028A (ja) | 2015-04-28 | 2024-02-09 | 抗ｐｄ－１抗体を使用するｐｄ－ｌ１陽性黒色腫の処置 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021037372A Pending JP2021105001A (ja) | 2015-04-28 | 2021-03-09 | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| JP2024018859A Pending JP2024063028A (ja) | 2015-04-28 | 2024-02-09 | 抗ｐｄ－１抗体を使用するｐｄ－ｌ１陽性黒色腫の処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20160362489A1 (https=) |
| EP (1) | EP3288980B1 (https=) |
| JP (3) | JP2018515474A (https=) |
| KR (2) | KR20250107941A (https=) |
| ES (1) | ES2861352T3 (https=) |
| WO (1) | WO2016176504A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
| HK1203971A1 (en) * | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| JP2018514550A (ja) | 2015-04-28 | 2018-06-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| EP4458417A3 (en) | 2015-08-11 | 2025-02-19 | Wuxi Biologics Ireland Limited | Novel anti-pd-1 antibodies |
| AU2016317915B2 (en) | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| SMT202500282T1 (it) * | 2015-11-18 | 2025-09-12 | Bristol Myers Squibb Co | Trattamento del cancro del polmone utilizzando una combinazione di un anticorpo anti-pd-1 e di un anticorpo anti-ctla-4 |
| JP7134168B6 (ja) | 2016-09-12 | 2024-02-02 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
| CN110300599B (zh) | 2016-12-07 | 2024-07-02 | 艾吉纳斯公司 | 抗体和其使用方法 |
| AU2018206481B2 (en) | 2017-01-09 | 2025-02-27 | Tesaro, Inc. | Methods of treating cancer with anti-PD-1 antibodies |
| US11161905B2 (en) * | 2017-03-04 | 2021-11-02 | Xiangtan Tenghua Bioscience | Recombinant antibodies to programmed death 1 (PD-1) and uses thereof |
| WO2018183408A1 (en) * | 2017-03-31 | 2018-10-04 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer with a combination of an antagonist of pd-1 and an anti-ctla4 antibody |
| EP3601355A1 (en) | 2017-03-31 | 2020-02-05 | Bristol-Myers Squibb Company | Methods of treating tumor |
| JP7382232B2 (ja) | 2017-05-02 | 2023-11-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CN110678200B (zh) | 2017-05-30 | 2024-05-17 | 百时美施贵宝公司 | 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物 |
| ES2965352T3 (es) | 2017-05-30 | 2024-04-12 | Bristol Myers Squibb Co | Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3) |
| EP3421607A1 (en) * | 2017-06-29 | 2019-01-02 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Identification and elimination of damaged and/or senescent cells |
| CN111247169A (zh) | 2017-10-15 | 2020-06-05 | 百时美施贵宝公司 | 治疗肿瘤的方法 |
| WO2019083971A1 (en) | 2017-10-23 | 2019-05-02 | Children's Medical Center Corporation | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY |
| US11767564B2 (en) | 2017-10-27 | 2023-09-26 | Board Of Regents, The University Of Texas System | Use of SDHA as a prognostic marker and therapeutic target in uveal melanoma |
| CN116327957A (zh) * | 2017-12-18 | 2023-06-27 | 德彪药业国际股份公司 | 治疗癌症的激动剂抗PD-1抗体与GnRH激动剂或GnRH拮抗剂的组合 |
| SG11202007590TA (en) | 2018-02-13 | 2020-09-29 | Merck Sharp & Dohme | Methods for treating cancer with anti-pd-1 antibodies |
| JP2021513540A (ja) * | 2018-02-13 | 2021-05-27 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗ｐｄ−１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 |
| JP7229565B2 (ja) * | 2018-03-21 | 2023-02-28 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | メラノーマを治療するための方法 |
| WO2020081408A1 (en) | 2018-10-18 | 2020-04-23 | Merck Sharp & Dohme Corp. | Formulations of anti-rsv antibodies and methods of use thereof |
| MX2021004928A (es) | 2018-10-31 | 2021-06-08 | Merck Sharp & Dohme Llc | Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos. |
| EP3880709A4 (en) * | 2018-11-05 | 2022-07-27 | Merck Sharp & Dohme Corp. | DOSING REGIME OF ANTI-LAG3 ANTIBODIES AND COMBINATION THERAPY WITH ANTI-PD-1 ANTIBODIES FOR THE TREATMENT OF CANCER |
| EP3876990A4 (en) | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
| WO2020118208A1 (en) * | 2018-12-07 | 2020-06-11 | Arizona Board Of Regents On Behalf Of The University Of Arizona | A method of determining risk for skin cancer development and skin cancer therapeutic prevention by measuring pd-1/pd-l1 signaling pathway members |
| WO2020146384A1 (en) * | 2019-01-07 | 2020-07-16 | Intra-Cellular Therapies, Inc. | Organic compounds |
| KR20220054853A (ko) | 2019-09-03 | 2022-05-03 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치료 방법 |
| CN113244386A (zh) * | 2020-02-13 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗肿瘤中的用途 |
| US12364695B2 (en) | 2020-06-02 | 2025-07-22 | Intra-Cellular Therapies, Inc. | Methods of treating inflammatory disease |
| KR20230093282A (ko) | 2020-10-23 | 2023-06-27 | 브리스톨-마이어스 스큅 컴퍼니 | 폐암에 대한 lag-3 길항제 요법 |
| JP2024522360A (ja) * | 2021-06-04 | 2024-06-18 | アムジエン・インコーポレーテツド | 抗ｃｃｒ８抗体及びその使用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| JP2003520828A (ja) | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート，エルエルシー | Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用 |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| CA2828940C (en) | 2011-03-10 | 2024-04-16 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| CA2840018C (en) | 2011-07-24 | 2019-07-16 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| HK1203971A1 (en) * | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| JP6595458B2 (ja) | 2013-09-20 | 2019-10-23 | ブリストル−マイヤーズ スクイブ カンパニー | 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ |
| WO2015176033A1 (en) | 2014-05-15 | 2015-11-19 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| CA2955612C (en) * | 2014-07-18 | 2022-05-17 | Advaxis, Inc. | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
| KR20250004095A (ko) | 2015-04-17 | 2025-01-07 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물 |
-
2016
- 2016-04-28 JP JP2017556652A patent/JP2018515474A/ja active Pending
- 2016-04-28 US US15/141,772 patent/US20160362489A1/en not_active Abandoned
- 2016-04-28 KR KR1020257021485A patent/KR20250107941A/ko active Pending
- 2016-04-28 KR KR1020177033883A patent/KR20170140316A/ko not_active Ceased
- 2016-04-28 ES ES16724512T patent/ES2861352T3/es active Active
- 2016-04-28 EP EP16724512.5A patent/EP3288980B1/en active Active
- 2016-04-28 WO PCT/US2016/029878 patent/WO2016176504A1/en not_active Ceased
-
2019
- 2019-06-03 US US16/430,106 patent/US20200010549A1/en not_active Abandoned
-
2021
- 2021-03-09 JP JP2021037372A patent/JP2021105001A/ja active Pending
-
2024
- 2024-02-09 JP JP2024018859A patent/JP2024063028A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515474A5 (https=) | ||
| JP2018514550A5 (https=) | ||
| JP2018522887A5 (https=) | ||
| JP2019510733A5 (https=) | ||
| JP2018520657A5 (https=) | ||
| JP2023159353A (ja) | Ｔ細胞疲弊を予防および逆転するためのエピジェネティック標的および転写標的の同定 | |
| PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| JP2016500251A5 (https=) | ||
| JP2021515566A5 (https=) | ||
| HRP20230237T1 (hr) | Anti-psma antitijela, bispecifične molekule za vezanje antigena koje vežu psma i cd3, i njihova uporaba | |
| RU2017116847A (ru) | Антитела к pd-1 | |
| EP4464333A3 (en) | Anti-death receptor antibodies and methods of use thereof | |
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| JOP20190248A1 (ar) | بروتينات ربط مولد ضد trem2 واستخداماته | |
| MX2021005565A (es) | Anticuerpos monoclonales antagonistas contra cumulo de diferenciacion 40 (cd40) y sus usos. | |
| RU2018107047A (ru) | Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения | |
| RU2018108048A (ru) | Новые анти-pd-1 антитела | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2018501197A5 (https=) | ||
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| PH12018502623A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| JP2020500542A5 (https=) | ||
| JP2017508475A5 (https=) | ||
| JP2018508483A5 (https=) | ||
| JP2017535257A5 (https=) |